Rare Disease Clinical Research & Operational Challenges

World Rare Disease Day is not just a date on the calendar!

Millions of people around the world live with conditions most of us have never heard of. Conditions that are often genetic, frequently diagnosed late and too often insufficiently understood.

Raising awareness is essential.

Generating measurable change is critical!

Progress in rare diseases depends on advancing research, accelerating accurate diagnosis, strengthening regulatory pathways and improving access to effective treatments.

While each rare disease affects a small population, collectively they represent a substantial and growing global health challenge, one that requires coordinated scientific, clinical and operational effort.

Globally, more than 7,000 rare diseases have been identified, with an estimated 250 new rare diseases discovered annually. The absence of a single international definition further complicates regulatory alignment and global drug development strategies.

Global Rare Disease Prevalence and Epidemiology

There are 6,000–8,000 unique rare diseases identified, approximately 80% of which are genetic in origin, and 50–75% present during childhood.

Globally, approximately 400 million individuals are impacted by rare diseases, and half of these are children.

Although rare diseases are common in aggregate, epidemiological data remain complex and sometimes inconsistent. Prevalence figures are frequently cited without robust validation, perpetuating misconceptions across medical and non-medical literature.

These data limitations directly influence clinical trial feasibility, recruitment planning, and regulatory strategy in rare disease drug development.

The Diagnostic Odyssey

Approximately half of individuals with suspected rare diseases remain undiagnosed.

For those who do receive a diagnosis, the pathway is often prolonged. Patients typically consult eight physicians and receive two to three misdiagnoses before achieving a correct genetic diagnosis, over an average period of 5.6–7.6 years.

Beyond the patient burden, this diagnostic delay creates inefficiencies within healthcare systems and delays appropriate intervention.

Treatment Gaps and Orphan Drug Development

The therapeutic gap remains substantial:

• Fewer than 3% of diagnosed rare diseases have a suitable drug treatment
• Even when considering approvals overall, 94% of rare diseases still lack an approved treatment

Where treatments exist, cost and development challenges remain significant:

• Rare disease drugs are reported to be up to 13.8 times more expensive than conventional therapies
• Orphan medicines demonstrate success rates as low as 6.2%, compared with 13.8% across all drugs

Rare disease drug development is structurally complex due to small patient populations, diversified phenotypes and genotypes, poorly understood natural history, and the lack of validated surrogate endpoints.

Despite these constraints, innovation continues across multiple therapeutic modalities, including small molecule drugs, antibody therapies, enzyme replacement therapies, gene therapy, stem cell therapy, small nucleic acid drugs, and drug repositioning strategies. Emerging modalities such as oligonucleotide therapy and gene therapy are reshaping treatment possibilities for previously untreatable rare genetic disorders.

Artificial Intelligence and Emerging Innovation

Machine learning and artificial intelligence technologies are influencing rare disease research and orphan drug development. AI can identify complex biological patterns, support predictive modelling of disease progression, and help identify subpopulations likely to respond to targeted therapies.

Next-generation genomics and improved data sharing have accelerated disease gene discovery, although remaining unsolved cases require novel methodological approaches.

Rare Disease Clinical Trials: Structural & Operational Complexity

Rare disease clinical trials introduce distinct methodological and operational challenges. Small and geographically dispersed patient populations, prolonged recruitment timelines, and expedited regulatory pathways create additional complexity.

New methodologies are required to streamline development, including improved data collection, better understanding of disease progression, refined endpoint definition, stronger regulatory benefit–risk evidence, and clearer demonstration of economic value.

Trials are frequently conducted in Duchenne muscular dystrophy, cystic fibrosis, Huntington’s disease, and various rare cancers and genetic disorders.

Why Sponsors Partner with SanaClis in Rare Disease Research

Rare disease programs require operational precision, integrated oversight & teams experienced in managing small, complex and highly specialized patient populations.

Sponsors partner with SanaClis because we deliver:

• Dedicated project teams (maximum 1–2 studies per Project Manager), ensuring sustained focus and proactive oversight
• 93% on-time and on-budget delivery, supporting predictable execution in high-complexity programs
• An integrated CRO + clinical supply chain model under one roof, reducing fragmentation and aligning operations with logistics
• Rare cancer and advanced modality expertise, including experience in complex and innovative therapeutic approaches
• Established site relationships capable of managing complex protocols and small patient populations

In rare disease research, where feasibility, timing, and precision coordination shape trial success, operational structure is a true strategic differentiator.

In Conclusion

Rare diseases illustrate a central reality in modern medicine: individually rare, collectively significant.

With up to 400 million people affected globally and 94% of conditions lacking approved treatment, rare diseases remain one of the most complex areas in clinical research.

Scientific innovation is advancing. Yet diagnostic delay, small patient populations, regulatory complexity, and access barriers remain structural challenges.

On World Rare Disease Day, awareness is the starting point. Sustainable progress requires continued research, operational discipline, and long-term commitment to improving outcomes for patients whose conditions may be rare, but whose needs are not.